Centessa receives FDA Fast Track for SerpinPC in hemophilia B

Centessa Pharmaceuticals plc

FDA granted Fast Track designation to SerpinPC, an investigational inhibitor of activated protein C.
SerpinPC is being developed for hemophilia B, with or without inhibitors.
Fast Track may enable expedited development and rolling review; CEO cites potential first-in-class subcutaneous therapy.
Centessa continues to advance PRESent registrational studies for SerpinPC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.